Form 4: Recursion Pharmaceuticals CFO Michael Secora Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Recursion Pharmaceuticals' Chief Financial Officer, Michael Secora, sold 11,937 shares of Class A Common Stock to cover tax obligations related to the vesting of restricted stock units.
Summary
- Michael Secora, the Chief Financial Officer of Recursion Pharmaceuticals, sold 11,937 shares of Class A Common Stock on November 15, 2024.
- The sale was executed at a price of $6.175 per share.
- This transaction was to cover tax withholding obligations related to the net settlement of restricted stock units.
- Following the transaction, Secora directly owns 1,487,694 shares of Class A Common Stock.
- Secora also holds multiple stock options with varying exercise prices and vesting schedules.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment towards the company's performance or future prospects.
Industry Context
This is a routine filing related to insider transactions and is common for executives who receive equity compensation. It does not indicate any specific trend or issue within the biotechnology industry.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, and the details of this filing are consistent with typical insider transactions.
- The sale of shares to cover tax obligations is a common practice among executives who receive equity compensation.
- The vesting schedules and exercise prices of the stock options are within the typical range for executive compensation packages in the biotech industry.
Stakeholder Impact
- The sale of shares by the CFO may have a minor impact on the stock price, but it is not expected to be significant given the relatively small number of shares sold.
Key Dates
| Date | Description |
|---|---|
| 02/04/2022 | Date of stock option grant with an exercise price of $11.40 and an expiration date of 02/04/2032. |
| 11/15/2024 | Date of the reported stock sale by Michael Secora. |
| 03/03/2030 | Expiration date of two stock option grants with an exercise price of $2.22. |
| 02/04/2032 | Expiration date of a stock option grant with an exercise price of $11.40. |
| 02/01/2033 | Expiration date of a stock option grant with an exercise price of $8.55. |
| 02/09/2034 | Expiration date of a stock option grant with an exercise price of $10.09. |
Keywords
Recursion Pharmaceuticals, Michael Secora, CFO, stock sale, Form 4, insider trading, Class A Common Stock, stock options, restricted stock units, tax obligations
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.